Roy D. Baynes
CIK 1680739 · Chief Medical Officer · last filed 2026-06-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.00M
Companies
7
Total Filings
68
Lifetime Open-Market Net
-$11.41M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TVTX | Director | 41,500 | $55.91 | $2.32M | -$3.09M | 13 | 2026-06-16 |
| NRIX | Director | — | $24.15 | — | $0 | 3 | 2026-05-15 |
| NTRA | Director | 18,512 | $252.22 | $4.67M | -$8.32M | 30 | 2026-04-28 |
| EIKN | Chief Medical Officer | — | $9.49 | — | $0 | 1 | 2026-03-04 |
| AARD | Director | — | $6.42 | — | $0 | 1 | 2025-06-13 |
| ATRA | Director | 1,740 | $7.81 | $13.6K | $0 | 5 | 2022-06-27 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 14,000 | — | — | $0 | 5 | 2020-05-19 |
Recent Filings · Page 2 of 7
68 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-04-14 | TVTX | Notice (144) | −32,750 | -$1.35M | EDGAR |
| 2026-04-07 | TVTX | Mixed | — | -$64.8K | EDGAR |
| 2026-04-06 | TVTX | Notice (144) | −10,000 | -$330.0K | EDGAR |
| 2026-03-04 | EIKN | Grant (A) | — | $0 | EDGAR |
| 2026-02-03 | NTRA | Grant (A) | +70 | $0 | EDGAR |
| 2025-11-21 | NTRA | Mixed | — | -$2.28M | EDGAR |
| 2025-11-20 | NTRA | Notice (144) | −7,668 | -$1.71M | EDGAR |
| 2025-11-19 | NTRA | Notice (144) | −5,112 | -$1.10M | EDGAR |
| 2025-11-04 | NTRA | Grant (A) | +93 | $0 | EDGAR |
| 2025-07-29 | NTRA | Grant (A) | +108 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.